News
Is Novavax Stock a Buy?
Novavax (NASDAQ: NVAX) has been a highly volatile stock in recent years, and that volatility is on full display again this month. Shares of the healthcare stock are up 200% since the start of May
Is Viking Therapeutics Stock a Buy?
Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster --
If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
If you'd invested $10,000 in Novavax (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant
1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?
Novavax (NASDAQ: NVAX) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this
Novavax Stock Just Tripled. Is It Too Late to Buy?
After losing more than 90% of its value from a peak back in 2021, Novavax (NASDAQ: NVAX) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global
How Viking Therapeutics Stock Could 30x
Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its
Is Viking Therapeutics the Best Biotech Stock for You?
Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to
Prediction: These 2 Growth Stocks Could Triple By 2030
Stocks that can triple in six years aren't easy to find. Doing so requires a compound annual growth rate of 20.1%, well above the broader market's historical performance. However, it isn't
Why Novavax Stock More Than Doubled Today
Shares of Novavax (NASDAQ: NVAX) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood can't seem to string together back-to-back years of success. The Ark Invest co-founder and CEO became a rock star among aggressive growth investors in 2020, only to see her
MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q1 2024 Earnings CallMay 09, 2024, 4:30 p.m. ET
Operator
Source Fool.com
CorMedix (CRMD) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q1 2024 Earnings CallMay 09, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q1 2024 Earnings CallMay 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
MannKind (MNKD) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q1 2024 Earnings CallMay 08, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2024 Earnings CallMay 08, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Agenus (AGEN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q1 2024 Earnings CallMay 07, 2024, 8:30 a.m. ET
Operator
Source Fool.com
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q1 2024 Earnings CallMay 06, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET
Operator
Source Fool.com
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's
Is Viking Therapeutics Incredibly Undervalued?
Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled
Can This High-Flying Stock 10x in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller